We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
The consensus mark for RXRX's Q4 loss and sales are pinned at 28 cents per share and $25.5M, respectively.
In late 2025, RXRX highlighted REC-4881 data showing rapid, durable polyp reductions in FAP patients.
RXRX advancing REC-1245, REC-617 and REC-3565, with new REC-102 set for phase I by late 2026.
Recursion Pharmaceuticals (RXRX - Free Report) , a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon.
The Zacks Consensus Estimate is pegged at a loss of 28 cents per share. The Zacks Consensus Estimate for fourth-quarter revenues is pinned at $25.5 million.
Let's see how things might have shaped up for the upcoming quarterly release.
Factors to Consider
In the absence of a marketed product, Recursion Pharmaceuticals only recognizes collaboration and grant revenues from its partners.
RXRX has ongoing collaboration agreements with pharmaceutical giants, including Roche, Bayer, Merck, and Sanofi, to develop candidates for several oncology indications with differentiated mechanisms of action. The company also collaborated with NVIDIA Corporation, the global leader in visual computing technologies, to develop a next-generation platform for the creation of novel therapies.
Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its fourth-quarter earnings call.
Recursion Pharmaceuticals’ lead candidate, REC-4881, is being evaluated in a phase Ib/II TUPELO study for familial adenomatous polyposis. In May 2025, the company reported preliminary data from this study and reported additional positive data in December 2025. REC-4881 drove rapid and durable reductions in polyp burden in FAP patients, providing the first clinical validation of the Recursion OS platform. The company plans to engage with the FDA in the first half of 2026 to discuss a potential registration pathway, while also expanding eligibility to younger patients and further refining the dosing strategy.
RXRX shares have plunged 36.8% in the past six months against the industry’s 21.1% growth.
Image Source: Zacks Investment Research
Recursion Pharmaceuticals’ ongoing phase I/II DAHLIA study is evaluating REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma. Data readout from the phase I portion of the DAHLIA study is expected in the first half of 2026. Recursion Pharmaceuticals is also developing a few other candidates, like REC-617 (advanced solid tumors) and REC-3565 (B-cell malignancies), in separate early-stage studies.
In 2025, Recursion Pharmaceuticals acquired Rallybio’s full stake in their joint venture for developing REV102 (now REC-102) and an associated backup molecule for the treatment of hypophosphatasia. REC-102, a potent and selective ENPP1 inhibitor with strong preclinical safety data, is expected to enter phase I studies by late 2026. Its oral formulation offers a major advantage over current enzyme replacement therapies, potentially improving patient adherence and reducing treatment-associated risks.
RXRX’s Earnings Surprise History
Recursion Pharmaceuticals has a mixed earnings surprise history so far. The company missed estimates in three of the trailing four reported quarters, beating on the remaining occasion, delivering an average negative surprise of 18.19%. In the last reported quarter, the company delivered a surprise of 5.26%.
Recursion Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Our proven model does not predict an earnings beat for Recursion Pharmaceuticals this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP of RXRX: Recursion Pharmaceuticals has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks Consensus Estimate are both pegged at a loss of 28 cents.
RXRX Zacks Rank: RXRX currently carries a Zacks Rank #2.
Stocks to Consider
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Castle Biosciences’ stock has risen 61.2% in the past six months. CSTL beat earnings estimates in three of the last four reported quarters, missing once, delivering an earnings surprise of 66.11%, on average. Castle Biosciences is scheduled to report fourth-quarter results on Feb. 26.
Immunovant (IMVT - Free Report) has an Earnings ESP of +2.13% and a Zacks Rank #3 at present.
Shares of IMVT have surged 68.7% in the past six months. Immunovant beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 9.51%.
Axsome Therapeutics (AXSM - Free Report) has an Earnings ESP of +30.00% and a Zacks Rank #3 at present.
Shares of AXSM have rallied 63.1% in the past six months. Axsome Therapeutics beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 8.47%. Axsome Therapeutics is slated to report fourth-quarter results on Feb. 23.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
Key Takeaways
Recursion Pharmaceuticals (RXRX - Free Report) , a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon.
The Zacks Consensus Estimate is pegged at a loss of 28 cents per share. The Zacks Consensus Estimate for fourth-quarter revenues is pinned at $25.5 million.
Let's see how things might have shaped up for the upcoming quarterly release.
Factors to Consider
In the absence of a marketed product, Recursion Pharmaceuticals only recognizes collaboration and grant revenues from its partners.
RXRX has ongoing collaboration agreements with pharmaceutical giants, including Roche, Bayer, Merck, and Sanofi, to develop candidates for several oncology indications with differentiated mechanisms of action. The company also collaborated with NVIDIA Corporation, the global leader in visual computing technologies, to develop a next-generation platform for the creation of novel therapies.
Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its fourth-quarter earnings call.
Recursion Pharmaceuticals’ lead candidate, REC-4881, is being evaluated in a phase Ib/II TUPELO study for familial adenomatous polyposis. In May 2025, the company reported preliminary data from this study and reported additional positive data in December 2025. REC-4881 drove rapid and durable reductions in polyp burden in FAP patients, providing the first clinical validation of the Recursion OS platform. The company plans to engage with the FDA in the first half of 2026 to discuss a potential registration pathway, while also expanding eligibility to younger patients and further refining the dosing strategy.
RXRX shares have plunged 36.8% in the past six months against the industry’s 21.1% growth.
Image Source: Zacks Investment Research
Recursion Pharmaceuticals’ ongoing phase I/II DAHLIA study is evaluating REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma. Data readout from the phase I portion of the DAHLIA study is expected in the first half of 2026. Recursion Pharmaceuticals is also developing a few other candidates, like REC-617 (advanced solid tumors) and REC-3565 (B-cell malignancies), in separate early-stage studies.
In 2025, Recursion Pharmaceuticals acquired Rallybio’s full stake in their joint venture for developing REV102 (now REC-102) and an associated backup molecule for the treatment of hypophosphatasia. REC-102, a potent and selective ENPP1 inhibitor with strong preclinical safety data, is expected to enter phase I studies by late 2026. Its oral formulation offers a major advantage over current enzyme replacement therapies, potentially improving patient adherence and reducing treatment-associated risks.
RXRX’s Earnings Surprise History
Recursion Pharmaceuticals has a mixed earnings surprise history so far. The company missed estimates in three of the trailing four reported quarters, beating on the remaining occasion, delivering an average negative surprise of 18.19%. In the last reported quarter, the company delivered a surprise of 5.26%.
Recursion Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Recursion Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Recursion Pharmaceuticals, Inc. Quote
Earnings Whispers for RXRX
Our proven model does not predict an earnings beat for Recursion Pharmaceuticals this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP of RXRX: Recursion Pharmaceuticals has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks Consensus Estimate are both pegged at a loss of 28 cents.
RXRX Zacks Rank: RXRX currently carries a Zacks Rank #2.
Stocks to Consider
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Castle Biosciences (CSTL - Free Report) has an Earnings ESP of +68.89% and sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Castle Biosciences’ stock has risen 61.2% in the past six months. CSTL beat earnings estimates in three of the last four reported quarters, missing once, delivering an earnings surprise of 66.11%, on average. Castle Biosciences is scheduled to report fourth-quarter results on Feb. 26.
Immunovant (IMVT - Free Report) has an Earnings ESP of +2.13% and a Zacks Rank #3 at present.
Shares of IMVT have surged 68.7% in the past six months. Immunovant beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 9.51%.
Axsome Therapeutics (AXSM - Free Report) has an Earnings ESP of +30.00% and a Zacks Rank #3 at present.
Shares of AXSM have rallied 63.1% in the past six months. Axsome Therapeutics beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 8.47%. Axsome Therapeutics is slated to report fourth-quarter results on Feb. 23.